GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Raphael Pharmaceutical Inc (OTCPK:RAPH) » Definitions » ROC (Joel Greenblatt) %

Raphael Pharmaceutical (Raphael Pharmaceutical) ROC (Joel Greenblatt) % : -87,520.00% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Raphael Pharmaceutical ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Raphael Pharmaceutical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -87,520.00%.

The historical rank and industry rank for Raphael Pharmaceutical's ROC (Joel Greenblatt) % or its related term are showing as below:

RAPH' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -182187.5   Med: -32224.22   Max: -367.71
Current: -182187.5

During the past 4 years, Raphael Pharmaceutical's highest ROC (Joel Greenblatt) % was -367.71%. The lowest was -182187.50%. And the median was -32224.22%.

RAPH's ROC (Joel Greenblatt) % is ranked worse than
99.72% of 1059 companies
in the Drug Manufacturers industry
Industry Median: 8.16 vs RAPH: -182187.50

Raphael Pharmaceutical's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Raphael Pharmaceutical ROC (Joel Greenblatt) % Historical Data

The historical data trend for Raphael Pharmaceutical's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Raphael Pharmaceutical ROC (Joel Greenblatt) % Chart

Raphael Pharmaceutical Annual Data
Trend Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
-367.71 -848.44 -165,850.00 -63,600.00

Raphael Pharmaceutical Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -68,800.00 -167,600.00 -562,400.00 -144,800.00 -87,520.00

Competitive Comparison of Raphael Pharmaceutical's ROC (Joel Greenblatt) %

For the Drug Manufacturers - Specialty & Generic subindustry, Raphael Pharmaceutical's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Raphael Pharmaceutical's ROC (Joel Greenblatt) % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Raphael Pharmaceutical's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Raphael Pharmaceutical's ROC (Joel Greenblatt) % falls into.



Raphael Pharmaceutical ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0.072 + 0 + 0)
=-0.072

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.063) - (0.456 + 0 + 0)
=-0.393

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Raphael Pharmaceutical for the quarter that ended in Mar. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-2.188/( ( (0.002 + max(-0.072, 0)) + (0.003 + max(-0.393, 0)) )/ 2 )
=-2.188/( ( 0.002 + 0.003 )/ 2 )
=-2.188/0.0025
=-87,520.00 %

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Raphael Pharmaceutical  (OTCPK:RAPH) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Raphael Pharmaceutical ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Raphael Pharmaceutical's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Raphael Pharmaceutical (Raphael Pharmaceutical) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
4 Lui Paster, Tel Aviv-Jaffa, ISR, 6803605
Raphael Pharmaceutical Inc is a pharmaceutical drug research and development company focused on the discovery and clinical development of life-improving drug therapies based on cannabinoids, including cannabidiol, or CBD oil.
Executives
Joseph Press director 4 LUI PASTER, TEL AVIV-JAFFA L3 6803605
Shlomo Pilo director, 10 percent owner, officer: Chief Executive Officer 4 LUI PASTER, TEL AVIV L3 6803605
Hayon Igal Louria director, officer: Chief Technology Officer 4 LUI PASTER, TEL AVIV-JAFFA L3 6803605
Yehuda Eliya director 4 LUI PASTER, TEL AVIV-JAFFA L3 6803605
Robert B Catell director 62 OSBORNE ROAD, GARDEN CITY NY 11530
Elisha Yanay director C/O ADVANCED TECHNOLOGY ACQUISITION CORP, 14 A ACHIMEIR STREET, RAMAT GAN L3 52587
Yacov A Shamash director
Guy Ofir director, 10 percent owner, officer: President 40 BAZ STREET, KARMIEL L3 20100
Emanuel Cohen director, 10 percent owner, officer: Secretary Treasurer Director 51 BILU STREET, RA'ANANA L3 00000

Raphael Pharmaceutical (Raphael Pharmaceutical) Headlines

No Headlines